FOR OVER 25 YEARS FIGHTING THE BIG INSURANCE COMPANIESFREE CONSULTATION

FDA – Avandia Data Under Review

Health officials from the Food and Drug Administration (FDA) recommend removing Avandia from the market due to its link to heart risks.

Avandia, manufactured by GlaxoSmithKline, is prescribed by doctors for the treatment of Type 2 Diabetes and is also known by its generic name, rosiglitazone or rosiglitazone maleate.

According to confidential agency reports, if every Avandia user was to switch medication, 500 heart attacks and 300 cases of heart failure would be averted every month. The diabetes drug was linked to 304 deaths in the third quarter of 2009.

Avandia’s heart risks first came to light in 2007 following a study by Cleveland Clinic. But, later studies were unable to show a definitive link.

An FDA advisory committee will assess whether or not the drug should remain on the market.

Diabetes is the seventh-leading cause of death in the United States.

Originally posted at InjuryBoard by Chrissie Cole